# A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)

Study · id `cardio:ct-nct02460159` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02460159](<https://clinicaltrials.gov/study/NCT02460159>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02460159

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 135 participants.

## Technical summary

Registry record NCT02460159. Non-randomized; no masking; primary purpose treatment. Start 2015-06-23 (actual); primary completion 2016-12-22 (actual). Results posted on 2018-01-11.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 135 participants (enrolled count; ClinicalTrials.gov record NCT02460159, source copy `cardio:ctgov-nct02460159-2024-05-16`, retrieved 2026-10-31)
- Started: 2015-06-23 (actual) (ClinicalTrials.gov record NCT02460159, source copy `cardio:ctgov-nct02460159-2024-05-16`, retrieved 2026-10-31)
- Primary completion: 2016-12-22 (actual) (ClinicalTrials.gov record NCT02460159, source copy `cardio:ctgov-nct02460159-2024-05-16`, retrieved 2026-10-31)
- Completion: 2016-12-22 (actual) (ClinicalTrials.gov record NCT02460159, source copy `cardio:ctgov-nct02460159-2024-05-16`, retrieved 2026-10-31)
- Results first posted: 2018-01-11 (ClinicalTrials.gov record NCT02460159, source copy `cardio:ctgov-nct02460159-2024-05-16`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02460159-2024-05-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
- Condition: Hypercholesterolemia
- Condition: Heterozygous Familial Hypercholesterolemia
- Intervention (Drug): EZ 10 mg/Atorva 20 mg FDC
- Intervention (Drug): EZ 10 mg/Atorva 10 mg FDC
- Lead sponsor: Organon and Co
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Organon and Co (`cardio:org-organon-and-co`)

## Provenance

Content hash: f4040c03e12ac7e86548fe6cf47f78a9d7b46d639af01b2abb941a5b16574fdb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
